title: [Inactivated poliovirus vaccines: an inevitable choice for eliminating poliomyelitis].
abstract: The inactivated poliovirus vaccine (IPV) is a very old tool in the fight against poliomyelitis. Though supplanted by oral poliovirus vaccine (OPV) in the 1960s and 1970s, the IPV has now become an inevitable choice because of the increasingly recognized risks associated with continuous use of OPVs. Following the pioneering work of Jonas Salk, who established key principles for the IPV, considerable experience has accumulated over the years. This work has led to modern Salk IPV-containing vaccines, based on the use of inactivated wildtype polioviruses, which have been deployed for routine use in many countries. Very good protection against paralysis is achieved with IPV through the presence of circulating antibodies able to neutralize virus infectivity toward motor neurons. In addition, with IPV, a variable degree of protection against mucosal infection (and therefore transmission) through mucosal antibodies and immune cells is achieved, depending on previous exposure of subjects to wildtype or vaccine polioviruses. The use of an IPV-followed-by-OPV sequential immunization schedule has the potential advantage of eliminating the vaccine-associated paralytic poliomyelitis (VAPP) risk, while limiting the risks of vaccine-derived poliovirus (VDPVs). Sabin strain-derived IPVs are new tools, only recently beginning to be deployed, and data are being generated to document their performance. IPVs will play an irreplaceable role in global eradication of polio.
authors.affiliation: Global Medical Affairs, Sanofi Pasteur, 69000 Lyon, France.
authors.forename: J D
authors.initials: JD
authors.lastname: Vidor
authors.forename: Shu
authors.initials: S
authors.lastname: Jean-Denis
mesh_terms: D002648:Child; D060740:Disease Eradication; D004196:Disease Outbreaks / Q000517:prevention & control*; D005838:Genotype; D006801:Humans; D007115:Immunization Schedule; D011051:Poliomyelitis / Q000517:prevention & control*; D017955:Poliovirus / Q000302:isolation & purification; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage* / Q000276:immunology; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage*
chemical_list: D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral